IP Verse

Crystalline L-Arginine Salt Of (R)-2-(7-(4-Cyclopentyl-3-(Trifluoromethyl)Benzyloxy)-1,2,3,4-Tetrahydrocyclo-Penta[B]Indol-3-Yl)Acetic Acid(Compound1) For Use In Sipi Receptor-Associated Disorders - EP3310760

The patent EP3310760 was granted to Arena Pharmaceuticals on Oct 19, 2022. The application was originally filed on Jun 21, 2016 under application number EP16734529A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3310760

ARENA PHARMACEUTICALS
Application Number
EP16734529A
Filing Date
Jun 21, 2016
Status
Granted And Under Opposition
Aug 12, 2022
Grant Date
Oct 19, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZJun 14, 2023KRAUS & LEDERER PARTGMBBADMISSIBLE
SCORPIOJun 14, 2023SAGITTARIUSADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO2010011316
DESCRIPTIONWO2011094008
INTERNATIONAL-SEARCH-REPORTWO2010011316
INTERNATIONAL-SEARCH-REPORTWO2011094008
OPPOSITIONWO2006060808
OPPOSITIONWO2010011316
OPPOSITIONWO2011094008

Non-Patent Literature (NPL) Citations (99) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- BALATONI ET AL., BRAIN RESEARCH BULLETIN, (2007), vol. 74, pages 307 - 316
DESCRIPTION- BAUMRUKER ET AL., EXPERT OPIN. INVESTIG. DRUGS, (2007), vol. 16, pages 283 - 289
DESCRIPTION- BAUMRUKER ET AL., EXPERT. OPIN. INVESTIG. DRUGS, (2007), vol. 16, pages 283 - 289
DESCRIPTION- BOLICK ET AL., ARTERIOSCLER. THROMB. VASE. BIOL., (2005), vol. 25, pages 976 - 981
DESCRIPTION- BRINKMANN ET AL., J. BIOL. CHEM., (2002), vol. 277, pages 21453 - 21457
DESCRIPTION- BRINKMANN ET AL., PHARMACOLOGY & THERAPEUTICS, (2007), vol. 115, pages 84 - 105
DESCRIPTION- BRINKMANN ET AL., TRANSPLANTATION, (2001), vol. 72, pages 764 - 769
DESCRIPTION- BRINKMANN ET AL., TRANSPLANT PROC., (2001), vol. 33, pages 530 - 531
DESCRIPTION- BRINKMANN, PHARMACOLOGY & THERAPEUTICS, (2007), vol. 115, pages 84 - 105
DESCRIPTION- BRUNAUER, S.; EMMETT, P. H.; TELLER, E., J. AM. CHEM. SOC., (1938), vol. 60, page 309
DESCRIPTION- BUZARD: D. J., ACS MED. CHEM. LETT., (2014), vol. 5, pages 1313 - 1317
DESCRIPTION- CHIBA ET AL., CELL MOL. BIOL., (2006), vol. 3, pages 11 - 19
DESCRIPTION- CHIBA, PHARMACOLOGY & THERAPEUTICS, (2005), vol. 108, pages 308 - 319
DESCRIPTION- CHUN, PHARMACOLOGICAL REVIEWS, (2002), vol. 54, pages 265 - 269
DESCRIPTION- COELHO ET AL., J. PHARMACOL. EXP. THER., (2007), vol. 323, pages 626 - 635
DESCRIPTION- DANIEL ET AL., J. IMMUNOL., (2007), vol. 178, pages 2458 - 2468
DESCRIPTION- DEGUCHI ET AL., ONCOLOGY REPORTS, (2006), vol. 16, pages 699 - 703
DESCRIPTION- DEV ET AL., PHARMACOLOGY AND THERAPEUTICS, (2008), vol. 117, pages 77 - 93
DESCRIPTION- D. NAKASHIMA ET AL., J. INVESTIGATIVE DERMATOLOGY, (2008), vol. 128, no. 12, pages 2833 - 2841
DESCRIPTION- E. BAR-HAIM ET AL., PLOS PATHOG, (2008), vol. 4, no. 11, page E1000211
DESCRIPTION- FU ET AL., TRANSPLANTATION, (2002), vol. 73, pages 1425 - 1430
DESCRIPTION- FUJII ET AL., AM. J. PHYSIOL. GASTROINTEST. LIVER PHYSIOL., (2006), vol. 291, pages G267 - G274
DESCRIPTION- FUJINO ET AL., J. PHARMACOL. EXP. THER., (2003), vol. 305, pages 70 - 77
DESCRIPTION- FUJISHIRO ET AL., J. HEART LUNG TRANSPLANT, (2006), vol. 25, pages 825 - 833
DESCRIPTION- HALE ET AL., BIOORG. MED. CHEM. LETT., (2004), vol. 14, pages 3351 - 3355
DESCRIPTION- HERZINGER ET AL., AM. J. CLIN. DERMATOL., (2007), vol. 8, pages 329 - 336
DESCRIPTION- HWANG ET AL., CIRCULATION, (1999), vol. 100, pages 1322 - 1329
DESCRIPTION- IDZKO ET AL., J. CLIN. INVEST., (2006), vol. 116, pages 2935 - 2944
DESCRIPTION- ISHII ET AL., NATURE, (2009), vol. 458, no. 7237, pages 524 - 528
DESCRIPTION- JOHAN GROENEVELD, VASCUL. PHARMACOL., (2003), vol. 39, pages 247 - 256
DESCRIPTION- JUNG ET AL., GLIA, (2007), vol. 55, pages 1656 - 1667
DESCRIPTION- KANEIDER ET AL., FASEB J., (2004), vol. 18, pages 309 - 311
DESCRIPTION- KAPPOS ET AL., N. ENGL. J. MED., (2006), vol. 355, pages 1124 - 1140
DESCRIPTION- KATAOKA ET AL., CELLULAR & MOLECULAR IMMUNOLOGY, (2005), vol. 2, pages 439 - 448
DESCRIPTION- KAUDEL ET AL., TRANSPLANT. PROC, (2007), vol. 39, pages 499 - 502
DESCRIPTION- KEUL ET AL., ARTERIOSCLER. THROMB. VASE. BIOL., (2007), vol. 27, pages 607 - 613
DESCRIPTION- KIM ET AL., CELL SIGNAL, (2004), vol. 16, pages 89 - 95
DESCRIPTION- KIMURA ET AL., STEM CELLS, (2007), vol. 25, pages 115 - 124
DESCRIPTION- KIYABAYASHI ET AL., J. CARDIOVASC. PHARMACOL., (2000), vol. 35, pages 410 - 416
DESCRIPTION- KOHNO ET AL., BIOL. PHARM. BULL., (2004), vol. 27, pages 1392 - 1396
DESCRIPTION- KORECK ET AL., DERMATOLOGY, (2003), vol. 206, pages 96 - 105
DESCRIPTION- KUROSE ET AL., EXP. EYE RES., (2000), vol. 70, pages 7 - 15
DESCRIPTION- LAMONTAGNE ET AL., CANCER RES., (2006), vol. 66, pages 221 - 231
DESCRIPTION- LEE ET AL., CLIN. CANCER RES., (2005), vol. 11, page 84588466
DESCRIPTION- LIMA ET AL., TRANSPLANT PROC., (2004), vol. 36, pages 1015 - 1017
DESCRIPTION- LIU ET AL., MICROSURGERY, (2007), vol. 27, pages 300 - 304
DESCRIPTION- MAKI ET AL., TRANSPLANTATION, (2002), vol. 74, pages 1684 - 1686
DESCRIPTION- MAKI ET AL., TRANSPLANTATION, (2005), vol. 79, pages 1051 - 1055
DESCRIPTION- MARTINI ET AL., AM. J. PHYSIOL. RENAL PHYSIOL., (2007), vol. 292, pages F1761 - F1770
DESCRIPTION- MARTINI ET AL., EXPERT OPIN. INVESTIG. DRUGS, (2007), vol. 16, pages 505 - 518
DESCRIPTION- MATLOUBIAN ET AL., NATURE, (2004), vol. 427, pages 355 - 360
DESCRIPTION- MATSUURA ET AL., INFLAMM. RES., (2000), vol. 49, pages 404 - 410
DESCRIPTION- MATSUURA ET AL., INT. J. IMMUNOPHARMACOL., (2000), vol. 22, pages 323 - 331
DESCRIPTION- MIRON ET AL., ANN. NEUROL., (2008), vol. 63, pages 61 - 71
DESCRIPTION- MIYAMOTO ET AL., J. AM. COLL. CARDIOL., (2001), vol. 37, pages 1713 - 1718
DESCRIPTION- MIZUSHIMA ET AL., INFLAMM. BOWEL DIS., (2004), vol. 10, pages 182 - 192
DESCRIPTION- NOFER ET AL., CIRCULATION, (2007), vol. 115, pages 501 - 508
DESCRIPTION- O. COSTU ET AL., JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, (2008), vol. 12, no. 3, pages 995 - 1004
DESCRIPTION- OGAWA ET AL., BBRC, (2007), vol. 361, pages 621 - 628
DESCRIPTION- OKAZAKI ET AL., J. RHEUMATOL., (2002), vol. 29, pages 707 - 716
DESCRIPTION- OO ET AL., J. BIOL. CHEM., (2007), vol. 282, pages 9082 - 9089
DESCRIPTION- PAN ET AL., CHEMISTRY & BIOLOGY, (2006), vol. 13, pages 1227 - 1234
DESCRIPTION- PREMENKO-LANIER ET AL., NATURE, (2008), vol. 454, page 894
DESCRIPTION- RAUSCH ET AL., J. MAGN. RESON. IMAGING, (2004), vol. 20, pages 16 - 24
DESCRIPTION- RAVENEY ET AL., ARCH. OPHTHALMOL., (2008), vol. 126, no. 10, page 1390
DESCRIPTION- ROSEN ET AL., IMMUNOL. REV., (2003), vol. 195, pages 160 - 177
DESCRIPTION- SAKAGAWA ET AL., TRANSPL. IMMUNOL., (2004), vol. 13, pages 161 - 168
DESCRIPTION- SANNA ET AL., J BIOL CHEM., (2004), vol. 279, pages 13839 - 13848
DESCRIPTION- SANNA ET AL., NAT CHEM BIOL., (2006), vol. 2, pages 434 - 441
DESCRIPTION- SAUER ET AL., J. BIOL. CHEM., (2004), vol. 279, pages 38471 - 38479
DESCRIPTION- SAWICKA ET AL., J. IMMUNOL., (2003), vol. 171, pages 6206 - 6214
DESCRIPTION- SCHMID ET AL., J. CELL BIOCHEM., (2007), vol. 101, pages 259 - 270
DESCRIPTION- SCHWAB ET AL., NATURE IMMUNOL., (2007), vol. 8, pages 1295 - 1301
DESCRIPTION- SHIMIZU ET AL., CIRCULATION, (2005), vol. 111, pages 222 - 229
DESCRIPTION- SUZUKI ET AL., J. HEART LUNG TRANSPLANT, (2006), vol. 25, pages 302 - 209
DESCRIPTION- SUZUKI ET AL., TRANSPL. IMMUNOL., (1996), vol. 4, pages 252 - 255
DESCRIPTION- TAYLOR ET AL., BLOOD, (2007), vol. 110, pages 3480 - 3488
DESCRIPTION- T. KOHONO ET AL., BIOLOGICAL & PHARMACEUTICAL BULLETIN, (2005), vol. 28, no. 4, pages 736 - 739
DESCRIPTION- TRUONG ET AL., AMERICAN JOURNAL OF TRANSPLANTATION, (2007), vol. 7, pages 2031 - 2038
DESCRIPTION- T SANCHEZ ET AL., J. BIOL. CHEM., (2003), vol. 278, no. 47, pages 47281 - 47290
DESCRIPTION- WEBB ET AL., J. NEUROIMMUNOL., (2004), vol. 153, pages 108 - 121
DESCRIPTION- WEBSTER, CUTIS, (2005), vol. 76, pages 4 - 7
DESCRIPTION- WHETZEL ET AL., CIRC. RES., (2006), vol. 99, pages 731 - 739
DESCRIPTION- YANAGAWA ET AL., J. IMMUNOL., (1998), vol. 160, pages 5493 - 5499
DESCRIPTION- YAN ET AL., BIOORG. & MED. CHEM. LETT., (2006), vol. 16, pages 3679 - 3683
DESCRIPTION- YANG ET AL., CLINICAL IMMUNOLOGY, (2003), vol. 107, pages 30 - 35
DESCRIPTION- ZHANG ET AL., J. CELL. MOL. MED., (2007), vol. 11, pages 307 - 314
DESCRIPTION- ZHANG ET AL., MINI-REVIEWS IN MEDICINAL CHEMISTRY, (2007), vol. 7, pages 845 - 850
INTERNATIONAL-SEARCH-REPORT- NORBERT RASENACK ET AL, "Crystal habit and tableting behavior", INTERNATIONAL JOURNAL OF PHARMACEUTICS, NL, (20020901), vol. 244, no. 1-2, doi:10.1016/S0378-5173(02)00296-X, ISSN 0378-5173, pages 45 - 57, XP055291502 [A] 1-75 * abstract * * page 46, column 1, lines 6-11 * * page 55, column 1, line 3 - column 2, line 8 * * page 56; table 5 * * Page 56, "Conclusions" *
OPPOSITION- Anonymous, "776 Optical microscopy", USP 35, (20120501), pages 331 - 333, XP093140987
OPPOSITION- Shawn X Yin, John A Grosso, "Selecting and controlling API crystal form for pharmaceutical development--strategies and processes", Current Opinion in Drug Discovery & Development, (20081100), vol. 11, no. 6, pages 771 - 777
OPPOSITION- Wei, H.y., "Computer-aided design and scale-up of crystallization processes: Integrating approaches and case studies", Chemical Engineering Research and Design, AMSTERDAM, NL, (20101001), vol. 88, no. 10, ISSN 0263-8762, pages 1377 - 1380, XP027382185
OPPOSITION- Nichols Gary, "Light Microscopy", Nichols Gary, Hilfiker Rolf, Polymorphism : in the Pharmaceutical Industry, Wiley, (20060101), pages 167 - 209, doi:10.1002/3527607889.ch7, ISBN 978-3-527-60788-4, XP093140997
OPPOSITION- Norbert Rasenack, Bernd W Müller, "Crystal habit and tableting behavior", International Journal of Pharmaceutics, ELSEVIER, NL, NL , (20020901), vol. 244, no. 1-2, doi:10.1016/S0378-5173(02)00296-X, ISSN 0378-5173, pages 45 - 57, XP055291502
OPPOSITION- Norbert Rasenack, Bernd W Müller, "Crystal habit and tableting behavior", International Journal of Pharmaceutics, NL , (20020901), vol. 244, no. 1-2, doi:10.1016/S0378-5173(02)00296-X, ISSN 0378-5173, pages 45 - 57, XP055291502
OPPOSITION- Stephen Byrn; Pfeiffer Ralph; Ganey Michael; Hoiberg Charles; Poochikian Guirag, "Pharmaceutical Solids: A strategic Approach to Regulatory Considerations", Environmental Science and Pollution Research, Berlin/Heidelberg, (19950701), vol. 12, no. 07, doi:10.1023/A:1016241927429, ISSN 0724-8741, pages 945 - 954, XP000996386
OPPOSITION- Wu Zhaohui, Yang Shuanglei, Wu Wei, "Application of temperature cycling for crystal quality control during crystallization", CrystEngComm, (20160101), vol. 18, no. 13, doi:10.1039/C5CE02522B, pages 2222 - 2238, XP055874263
OPPOSITION- Ticehurst Martyn David, Marziano Ivan, "Integration of active pharmaceutical ingredient solid form selection and particle engineering into drug product design", Journal of pharmacy and pharmacology : JPP, John Wiley & Sons Ltd, London, GB, GB , (20150601), vol. 67, no. 6, doi:10.1111/jphp.12375, ISSN 0022-3573, pages 782 - 802, XP093303088
OPPOSITION- Banga Sheere; Chawla Garima; Varandani Deepak; Mehta B R; Bansal Arvind K, "Modification of the crystal habit of celecoxib for improved processability", Journal of pharmacy and pharmacology : JPP, John Wiley & Sons Ltd, London, GB, GB , (20070101), vol. 59, no. 1, doi:10.1211/jpp.59.1.0005, ISSN 0022-3573, pages 29 - 39, XP009145820

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents